MontoyaValcyte regimen

Discussion in 'Fibromyalgia Main Forum' started by winsomme, Feb 1, 2007.

  1. winsomme

    winsomme New Member

    sorry for another thread on this topic, but i still am hoping to clarify this.

    i just read in a summary of the HHV-6 conference that took play in Spain MAy 2006 that in the maintanance phase Montoya used 900mg a day.

    is that 450mg 2 times a day or 900mg once a day?

    if anybody has seem Dr Montoya could they clarify the dosage in the maintance phase?

  2. ravenpaige

    ravenpaige New Member


    From the Montoya article:

    "Valganciclovir (VGCV) was prescribed as 900 mg twice
    per day for three weeks followed by 900 mg every day
    to complete a total of 6 months on the drug."
  3. pawprints

    pawprints New Member

    Hoping to find out if this is once or twice a day.

  4. winsomme

    winsomme New Member


    thanks for the quote. do you know where you found that?

    it is still a little unclear if it is 450mg 2 times a day for a total of 900mg, or just 900mg once a day.

    i have seen it listed both ways, and since he seems to have such a good success rate, it might be worth not deviating.

    in the end, it might not really matter too...

  5. ravenpaige

    ravenpaige New Member


    The quote came from Montoya's full article in the Journal of Clinical Virology: Journal of Clinical Virology 37 Suppl. 1 (2006) S33–S38. You can download the full article from for a fee, I believe it was $30.

    However, the article was not really clear on whether it was once or twice a day as maintenance; but since it was specified as 900 mg twice per day, then 900 mg everyday, I would tend to assume that the maintenance dosage was just once a day.

    Here's the entire section on Drug regimen, toxicity monitoring and fatigue evaluation from the article (below):

    2.2. Drug regimen, toxicity monitoring, and fatigue
    Valganciclovir (VGCV) was prescribed as 900 mg twice
    per day for three weeks followed by 900 mg every day
    to complete a total of 6 months on the drug. Ganciclovir
    was approved in June 1989 by the United States Food and
    Drug Administration for the treatment and prophylaxis of
    diseases caused by cytomegalovirus (CMV). Ganciclovir
    has been used at Stanford Medical Center since 1987
    for the treatment of several viral diseases observed in
    immunocompromised patients (Montoya, 2004). A second
    oral formulation (valganciclovir or L-valine esther of
    ganciclovir) was introduced in 1991 and achieves serum
    levels similar to those reached by the intravenous form.
    CBC’s were followed twice per week for three weeks,
    followed by once per week for three weeks, and once per
    month thereafter until VGCV was discontinued. None of the
    patients in our cohort was taking drugs with known adverse
    hematological or renal effects.
    While on VGCV, patients were instructed to report
    any new symptoms and on each medical visit they were
    explicitly asked whether they had experienced fever, chills,
    unusual bleeding or bruising, infection, unhealed sores or
    white plaques in mouth, headache, seizures or gastrointestinal
    symptoms. Pregnancy was not a consideration for any
    of our patients in the childbearing age; none of them was
    sexually active. At baseline, and again at each visit, patients
    were asked to report on their current activity level as a
    percentage of their pre-illness activity level.

[ advertisement ]